Archi Indonesia Tbk vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Archi Indonesia Tbk trades at Rp1,220 (market cap 30.28T, 11.88M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp238 (market cap 164.65B, 50.3K 24h volume). The key difference: Archi Indonesia Tbk is far larger — about 183.9× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Archi Indonesia Tbk is more actively traded (11.88M versus 50.3K). Which is the better fit depends on your goals.
| ARCI | OBAT | |
|---|---|---|
Market Cap | 30.28T | 164.65B |
Volume | 11.88M | 50.3K |
Lot | 118.78K | 503 |
Turnover | 14.26B | 12.13M |
Average Price | 1,200.22 | 241.18 |
Value | 14.26B | 12.13M |
Indicative Equilibrium Price | 1,180 | 238 |
Indicative Equilibrium Volume | 3.67K | 100 |
Trailing returns across standard periods
Latest headlines on both assets
PT Archi Indonesia Tbk. (the Company) was established based on Notarial Deed No. 1 of Fatma Agung Budiwijaya, S.H., dated September 14, 2010. The Company commenced its commercial operations in 2010 and is primarily involved in investment holding. PT Rajawali Corpora is the Companys parent and ultimate parent entity.
Read more on ARCI →PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →